3 Safest Stocks to Buy Now
With the S&P 500 now in correction and stocks selling…
Sell
48
XBI Quote, Financials, Valuation and Earnings
Last price:
$87.13
Seasonality move
:
2.48%
Day range:
$85.44 - $88.21
52-week range:
$81.14 - $105.47
Dividend yield:
0.15%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
7.7M
Avg. volume:
9.1M
1-year change:
-11.46%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
XBI
SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- |
|
ARKG
ARK Genomic Revolution ETF
|
-- | -- | -- | -- | -- |
|
LABU
Direxion Daily S&P Biotech Bull 3X Shares
|
-- | -- | -- | -- | -- |
|
PSCH
Invesco S&P SmallCap Health Care ETF
|
-- | -- | -- | -- | -- |
|
PTH
Invesco Dorsey Wright Healthcare Momentum ETF
|
-- | -- | -- | -- | -- |
|
SBIO
ALPS Medical Breakthroughs ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
XBI
SPDR S&P Biotech ETF
|
$87.15 | -- | -- | -- | $0.00 | 0.15% | -- |
|
ARKG
ARK Genomic Revolution ETF
|
$22.03 | -- | -- | -- | $0.00 | 0% | -- |
|
LABU
Direxion Daily S&P Biotech Bull 3X Shares
|
$74.08 | -- | -- | -- | $0.15 | 0.76% | -- |
|
PSCH
Invesco S&P SmallCap Health Care ETF
|
$41.00 | -- | -- | -- | $0.02 | 0.29% | -- |
|
PTH
Invesco Dorsey Wright Healthcare Momentum ETF
|
$38.27 | -- | -- | -- | $0.03 | 0.07% | -- |
|
SBIO
ALPS Medical Breakthroughs ETF
|
$30.47 | -- | -- | -- | $1.17 | 3.85% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
XBI
SPDR S&P Biotech ETF
|
-- | 1.588 | -- | -- |
|
ARKG
ARK Genomic Revolution ETF
|
-- | 2.857 | -- | -- |
|
LABU
Direxion Daily S&P Biotech Bull 3X Shares
|
-- | 4.050 | -- | -- |
|
PSCH
Invesco S&P SmallCap Health Care ETF
|
-- | 2.008 | -- | -- |
|
PTH
Invesco Dorsey Wright Healthcare Momentum ETF
|
-- | 1.594 | -- | -- |
|
SBIO
ALPS Medical Breakthroughs ETF
|
-- | 1.265 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
XBI
SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- | -- |
|
ARKG
ARK Genomic Revolution ETF
|
-- | -- | -- | -- | -- | -- |
|
LABU
Direxion Daily S&P Biotech Bull 3X Shares
|
-- | -- | -- | -- | -- | -- |
|
PSCH
Invesco S&P SmallCap Health Care ETF
|
-- | -- | -- | -- | -- | -- |
|
PTH
Invesco Dorsey Wright Healthcare Momentum ETF
|
-- | -- | -- | -- | -- | -- |
|
SBIO
ALPS Medical Breakthroughs ETF
|
-- | -- | -- | -- | -- | -- |
SPDR S&P Biotech ETF vs. Competitors
-
Which has Higher Returns XBI or ARKG?
ARK Genomic Revolution ETF has a net margin of -- compared to SPDR S&P Biotech ETF's net margin of --. SPDR S&P Biotech ETF's return on equity of -- beat ARK Genomic Revolution ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XBISPDR S&P Biotech ETF-- -- -- ARKGARK Genomic Revolution ETF-- -- -- -
What do Analysts Say About XBI or ARKG?
SPDR S&P Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand ARK Genomic Revolution ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Biotech ETF has higher upside potential than ARK Genomic Revolution ETF, analysts believe SPDR S&P Biotech ETF is more attractive than ARK Genomic Revolution ETF.
Company Buy Ratings Hold Ratings Sell Ratings XBISPDR S&P Biotech ETF0 0 0 ARKGARK Genomic Revolution ETF0 0 0 -
Is XBI or ARKG More Risky?
SPDR S&P Biotech ETF has a beta of 1.028, which suggesting that the stock is 2.824% more volatile than S&P 500. In comparison ARK Genomic Revolution ETF has a beta of 1.699, suggesting its more volatile than the S&P 500 by 69.933%.
-
Which is a Better Dividend Stock XBI or ARKG?
SPDR S&P Biotech ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0.15%. ARK Genomic Revolution ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SPDR S&P Biotech ETF pays -- of its earnings as a dividend. ARK Genomic Revolution ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XBI or ARKG?
SPDR S&P Biotech ETF quarterly revenues are --, which are smaller than ARK Genomic Revolution ETF quarterly revenues of --. SPDR S&P Biotech ETF's net income of -- is lower than ARK Genomic Revolution ETF's net income of --. Notably, SPDR S&P Biotech ETF's price-to-earnings ratio is -- while ARK Genomic Revolution ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Biotech ETF is -- versus -- for ARK Genomic Revolution ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XBISPDR S&P Biotech ETF-- -- -- -- ARKGARK Genomic Revolution ETF-- -- -- --
-
Which has Higher Returns XBI or LABU?
Direxion Daily S&P Biotech Bull 3X Shares has a net margin of -- compared to SPDR S&P Biotech ETF's net margin of --. SPDR S&P Biotech ETF's return on equity of -- beat Direxion Daily S&P Biotech Bull 3X Shares's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XBISPDR S&P Biotech ETF-- -- -- LABUDirexion Daily S&P Biotech Bull 3X Shares-- -- -- -
What do Analysts Say About XBI or LABU?
SPDR S&P Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Direxion Daily S&P Biotech Bull 3X Shares has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Biotech ETF has higher upside potential than Direxion Daily S&P Biotech Bull 3X Shares, analysts believe SPDR S&P Biotech ETF is more attractive than Direxion Daily S&P Biotech Bull 3X Shares.
Company Buy Ratings Hold Ratings Sell Ratings XBISPDR S&P Biotech ETF0 0 0 LABUDirexion Daily S&P Biotech Bull 3X Shares0 0 0 -
Is XBI or LABU More Risky?
SPDR S&P Biotech ETF has a beta of 1.028, which suggesting that the stock is 2.824% more volatile than S&P 500. In comparison Direxion Daily S&P Biotech Bull 3X Shares has a beta of 3.061, suggesting its more volatile than the S&P 500 by 206.128%.
-
Which is a Better Dividend Stock XBI or LABU?
SPDR S&P Biotech ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0.15%. Direxion Daily S&P Biotech Bull 3X Shares offers a yield of 0.76% to investors and pays a quarterly dividend of $0.15 per share. SPDR S&P Biotech ETF pays -- of its earnings as a dividend. Direxion Daily S&P Biotech Bull 3X Shares pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XBI or LABU?
SPDR S&P Biotech ETF quarterly revenues are --, which are smaller than Direxion Daily S&P Biotech Bull 3X Shares quarterly revenues of --. SPDR S&P Biotech ETF's net income of -- is lower than Direxion Daily S&P Biotech Bull 3X Shares's net income of --. Notably, SPDR S&P Biotech ETF's price-to-earnings ratio is -- while Direxion Daily S&P Biotech Bull 3X Shares's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Biotech ETF is -- versus -- for Direxion Daily S&P Biotech Bull 3X Shares. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XBISPDR S&P Biotech ETF-- -- -- -- LABUDirexion Daily S&P Biotech Bull 3X Shares-- -- -- --
-
Which has Higher Returns XBI or PSCH?
Invesco S&P SmallCap Health Care ETF has a net margin of -- compared to SPDR S&P Biotech ETF's net margin of --. SPDR S&P Biotech ETF's return on equity of -- beat Invesco S&P SmallCap Health Care ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XBISPDR S&P Biotech ETF-- -- -- PSCHInvesco S&P SmallCap Health Care ETF-- -- -- -
What do Analysts Say About XBI or PSCH?
SPDR S&P Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco S&P SmallCap Health Care ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Biotech ETF has higher upside potential than Invesco S&P SmallCap Health Care ETF, analysts believe SPDR S&P Biotech ETF is more attractive than Invesco S&P SmallCap Health Care ETF.
Company Buy Ratings Hold Ratings Sell Ratings XBISPDR S&P Biotech ETF0 0 0 PSCHInvesco S&P SmallCap Health Care ETF0 0 0 -
Is XBI or PSCH More Risky?
SPDR S&P Biotech ETF has a beta of 1.028, which suggesting that the stock is 2.824% more volatile than S&P 500. In comparison Invesco S&P SmallCap Health Care ETF has a beta of 1.020, suggesting its more volatile than the S&P 500 by 1.957%.
-
Which is a Better Dividend Stock XBI or PSCH?
SPDR S&P Biotech ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0.15%. Invesco S&P SmallCap Health Care ETF offers a yield of 0.29% to investors and pays a quarterly dividend of $0.02 per share. SPDR S&P Biotech ETF pays -- of its earnings as a dividend. Invesco S&P SmallCap Health Care ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XBI or PSCH?
SPDR S&P Biotech ETF quarterly revenues are --, which are smaller than Invesco S&P SmallCap Health Care ETF quarterly revenues of --. SPDR S&P Biotech ETF's net income of -- is lower than Invesco S&P SmallCap Health Care ETF's net income of --. Notably, SPDR S&P Biotech ETF's price-to-earnings ratio is -- while Invesco S&P SmallCap Health Care ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Biotech ETF is -- versus -- for Invesco S&P SmallCap Health Care ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XBISPDR S&P Biotech ETF-- -- -- -- PSCHInvesco S&P SmallCap Health Care ETF-- -- -- --
-
Which has Higher Returns XBI or PTH?
Invesco Dorsey Wright Healthcare Momentum ETF has a net margin of -- compared to SPDR S&P Biotech ETF's net margin of --. SPDR S&P Biotech ETF's return on equity of -- beat Invesco Dorsey Wright Healthcare Momentum ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XBISPDR S&P Biotech ETF-- -- -- PTHInvesco Dorsey Wright Healthcare Momentum ETF-- -- -- -
What do Analysts Say About XBI or PTH?
SPDR S&P Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Dorsey Wright Healthcare Momentum ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Biotech ETF has higher upside potential than Invesco Dorsey Wright Healthcare Momentum ETF, analysts believe SPDR S&P Biotech ETF is more attractive than Invesco Dorsey Wright Healthcare Momentum ETF.
Company Buy Ratings Hold Ratings Sell Ratings XBISPDR S&P Biotech ETF0 0 0 PTHInvesco Dorsey Wright Healthcare Momentum ETF0 0 0 -
Is XBI or PTH More Risky?
SPDR S&P Biotech ETF has a beta of 1.028, which suggesting that the stock is 2.824% more volatile than S&P 500. In comparison Invesco Dorsey Wright Healthcare Momentum ETF has a beta of 0.902, suggesting its less volatile than the S&P 500 by 9.824%.
-
Which is a Better Dividend Stock XBI or PTH?
SPDR S&P Biotech ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0.15%. Invesco Dorsey Wright Healthcare Momentum ETF offers a yield of 0.07% to investors and pays a quarterly dividend of $0.03 per share. SPDR S&P Biotech ETF pays -- of its earnings as a dividend. Invesco Dorsey Wright Healthcare Momentum ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XBI or PTH?
SPDR S&P Biotech ETF quarterly revenues are --, which are smaller than Invesco Dorsey Wright Healthcare Momentum ETF quarterly revenues of --. SPDR S&P Biotech ETF's net income of -- is lower than Invesco Dorsey Wright Healthcare Momentum ETF's net income of --. Notably, SPDR S&P Biotech ETF's price-to-earnings ratio is -- while Invesco Dorsey Wright Healthcare Momentum ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Biotech ETF is -- versus -- for Invesco Dorsey Wright Healthcare Momentum ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XBISPDR S&P Biotech ETF-- -- -- -- PTHInvesco Dorsey Wright Healthcare Momentum ETF-- -- -- --
-
Which has Higher Returns XBI or SBIO?
ALPS Medical Breakthroughs ETF has a net margin of -- compared to SPDR S&P Biotech ETF's net margin of --. SPDR S&P Biotech ETF's return on equity of -- beat ALPS Medical Breakthroughs ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XBISPDR S&P Biotech ETF-- -- -- SBIOALPS Medical Breakthroughs ETF-- -- -- -
What do Analysts Say About XBI or SBIO?
SPDR S&P Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand ALPS Medical Breakthroughs ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Biotech ETF has higher upside potential than ALPS Medical Breakthroughs ETF, analysts believe SPDR S&P Biotech ETF is more attractive than ALPS Medical Breakthroughs ETF.
Company Buy Ratings Hold Ratings Sell Ratings XBISPDR S&P Biotech ETF0 0 0 SBIOALPS Medical Breakthroughs ETF0 0 0 -
Is XBI or SBIO More Risky?
SPDR S&P Biotech ETF has a beta of 1.028, which suggesting that the stock is 2.824% more volatile than S&P 500. In comparison ALPS Medical Breakthroughs ETF has a beta of 0.934, suggesting its less volatile than the S&P 500 by 6.615%.
-
Which is a Better Dividend Stock XBI or SBIO?
SPDR S&P Biotech ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0.15%. ALPS Medical Breakthroughs ETF offers a yield of 3.85% to investors and pays a quarterly dividend of $1.17 per share. SPDR S&P Biotech ETF pays -- of its earnings as a dividend. ALPS Medical Breakthroughs ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XBI or SBIO?
SPDR S&P Biotech ETF quarterly revenues are --, which are smaller than ALPS Medical Breakthroughs ETF quarterly revenues of --. SPDR S&P Biotech ETF's net income of -- is lower than ALPS Medical Breakthroughs ETF's net income of --. Notably, SPDR S&P Biotech ETF's price-to-earnings ratio is -- while ALPS Medical Breakthroughs ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Biotech ETF is -- versus -- for ALPS Medical Breakthroughs ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XBISPDR S&P Biotech ETF-- -- -- -- SBIOALPS Medical Breakthroughs ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Tesla Stock: The Bear Case
The recent stock market drop has been a punishing time…
Is VUG a Good ETF to Buy?
For the last few years, earnings growth from the tech…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Alerts
Sell
5
CABO alert for Mar 14
Cable One [CABO] is down 3.97% over the past day.
Sell
38
ADBE alert for Mar 14
Adobe [ADBE] is up 4.43% over the past day.
Sell
29
CAR alert for Mar 14
Avis Budget Group [CAR] is up 11.68% over the past day.
